Abstract
Aortic aneurysms account for 10,000 deaths annually in the UK, due to rupture. At present the only effective therapeutic strategy to treat abdominal aortic aneurysms is to surgically repair them; this carries an elective mortality of up to 10%. Recent advances in vascular biology have led to a greater understanding of the pathophysiological process that causes aortic aneurysms to expand and rupture. Key pathological processes include widespread aortic inflammation, proteolytic degradation of the extracellular matrix, neovascularisation and generation of reactive oxygen species. Identification of these processes has lead to pharmacological strategies to prevent aneurysm expansion and rupture. Many of these strategies have undergone proof of concept in animal models and some have now entered clinical trials. This review outlines current thinking regarding the molecular events leading to aneurysm expansion and explains how these processes may be inhibited. Experimental data on agents retarding aneurysm expansion in animal models are discussed. A significant proportion of the review details pharmacological agents that have undergone or are undergoing clinical trials. Pharmacological treatment for abdominal aneurysms is urgently required given the number of small aneurysms being diagnosed by screening programmes. This is a rapidly evolving field and one in which translation from experimental research to clinical practice is anticipated within 5 years.
Keywords: Abdominal, aortic, aneurysm, pharmacotherapy, pharmacology, medical, management
Current Vascular Pharmacology
Title: Pharmacotherapy of Abdominal Aortic Aneurysms
Volume: 4 Issue: 2
Author(s): Joe Dawson, Edward Choke, Saiqa Sayed, Gillian Cockerill, Ian Loftus and Matt M. Thompson
Affiliation:
Keywords: Abdominal, aortic, aneurysm, pharmacotherapy, pharmacology, medical, management
Abstract: Aortic aneurysms account for 10,000 deaths annually in the UK, due to rupture. At present the only effective therapeutic strategy to treat abdominal aortic aneurysms is to surgically repair them; this carries an elective mortality of up to 10%. Recent advances in vascular biology have led to a greater understanding of the pathophysiological process that causes aortic aneurysms to expand and rupture. Key pathological processes include widespread aortic inflammation, proteolytic degradation of the extracellular matrix, neovascularisation and generation of reactive oxygen species. Identification of these processes has lead to pharmacological strategies to prevent aneurysm expansion and rupture. Many of these strategies have undergone proof of concept in animal models and some have now entered clinical trials. This review outlines current thinking regarding the molecular events leading to aneurysm expansion and explains how these processes may be inhibited. Experimental data on agents retarding aneurysm expansion in animal models are discussed. A significant proportion of the review details pharmacological agents that have undergone or are undergoing clinical trials. Pharmacological treatment for abdominal aneurysms is urgently required given the number of small aneurysms being diagnosed by screening programmes. This is a rapidly evolving field and one in which translation from experimental research to clinical practice is anticipated within 5 years.
Export Options
About this article
Cite this article as:
Dawson Joe, Choke Edward, Sayed Saiqa, Cockerill Gillian, Loftus Ian and Thompson M. Matt, Pharmacotherapy of Abdominal Aortic Aneurysms, Current Vascular Pharmacology 2006; 4 (2) . https://dx.doi.org/10.2174/157016106776359817
DOI https://dx.doi.org/10.2174/157016106776359817 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Contrast-Induced Nephropathy after Endovascular Aneurysm Repair, Carotid and Peripheral Interventions
Current Vascular Pharmacology Multimodality Imaging for Interventional Cardiology
Current Pharmaceutical Design Prognostic and Predictive Value of Epithelial to Mesenchymal Transitionassociated Markers in Oral Squamous Cell Carcinoma
Current Proteomics From Biomarkers to Cytokine-like Hormones: Uncovering New Directives for Cognitive Loss and Alzheimer’s Disease
Current Neurovascular Research The Predictive Value of Lipid Markers in Vascular Disease
Current Pharmaceutical Design Microdialysis as an Excellent Sampling Approach for Biomedical Analysis
Current Pharmaceutical Analysis Myocardial Infarction Following Atherosclerosis in Murine Models
Current Drug Targets Mineralocorticoid Receptor Blockade in the Protection of Target Organ Damage
Cardiovascular & Hematological Agents in Medicinal Chemistry Anti-Platelet Treatment of Middle-Sized Abdominal Aortic Aneurysms
Current Vascular Pharmacology A Concise Update on the Relevance of Secretory Phospholipase A2 Group IIA and its Inhibitors with Cancer
Medicinal Chemistry Non Smoking for Successful Aging: Therapeutic Perspectives
Current Pharmaceutical Design Free Radicals Generated by Post-Prandial Oxidative Burst in the Early Alterations of Vascular Contractility
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued) Optical Imaging of Microvascular Morphology and Perfusion
Current Angiogenesis (Discontinued) Current Status of Rho-Associated Kinases (ROCKs) in Coronary Atherosclerosis and Vasospasm
Cardiovascular & Hematological Agents in Medicinal Chemistry Neuroimaging of Non-Accidental Injury
Current Pediatric Reviews Heparin-Coated Extracorporeal Circulation Systems in Heart Surgery
Recent Patents on Cardiovascular Drug Discovery Epidemiology and Management of Infectious Complications in Contemporary Management of Chronic Leukemias
Infectious Disorders - Drug Targets Intracranial Non-traumatic Aneurysms in Children and Adolescents
Current Pediatric Reviews Proteomics and Cardiovascular Disease: An Update
Current Medicinal Chemistry Imaging of Spinal Bone Tumors: Principles and Practice
Current Medical Imaging